This could be due to the efficacy of Ulocuplumab which may rely on CXCR4 mutations in leukemia cells, to the adverse effects such as reversible thrombocytopenia, which must be closely monitored, and to the fact that new medications in chronic leukemia must exhibit considerable improvements over existing therapy to gain widespread use [43]. Here, CXCR4 is linked to Thrombocytopenia.